1、The current high ground of global innovative drugs, I believe, isADC (Antibody-Drug Conjugate)）。 (1)In 2023, the global market size ofADC reached 10.4 billion USD, and it is expected to reach 64.7 billion USD by 2030, with a compound annual growth rate of about 30%, significantly higher than the overall growth rate of biopharmaceuticals. In comparison, … Read more
At the recent 2025 European Hematology Association (EHA) Annual Meeting and the International Conference on Malignant Lymphoma (ICML), not only were continuous breakthroughs in the field of lymphoma treatment witnessed, but a series of studies also validated the immense potential of precision immunotherapy in enhancing patient survival benefits. “Blood News” focuses on this international event, … Read more
▎Trace Back Three years ago, when I wrote analyses on the CD3 bispecific antibody combined ADC, it was often considered an overly aggressive therapy. However, Roche has made significant explorations in this area. When the CD3/DLL3 ADC from Wuxi Biologics was released, many in the industry were puzzled, but there is no need for surprise. … Read more
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting grandly opened in Chicago on May 31, lasting for 4 days, with the theme “Driving Knowledge to Action: Building a Better Future,” focusing on the latest research progress and innovative translational achievements in the global cancer treatment field. ADC drugs remain a hot area of … Read more
We previously mentioned that the current standard treatment for cancer is gradually shifting from PD-1 + chemotherapy to PD-1 + ADC drugs. According to relevant data, the global ADC drug market size has grown from $7.9 billion in 2022 to approximately $20 billion in 2024, showing strong growth momentum. Among them, DS8201 (HER2 ADC), jointly … Read more
Click the blue text Follow us This Issue Focus Point B7-H4 is a member of the B7 immune checkpoint ligand family, which has been shown to bind to an unknown receptor on T cells, inhibiting T cell proliferation and cytokine production, thereby negatively regulating T cell function. The expression level of B7-H4 is elevated in … Read more
Click the blue text to follow meOn the battlefield against cancer, a new type of “weapon” is rising – the ADC (Antibody-Drug Conjugate) anti-cancer drug independently developed in China. The emergence of this drug has not only attracted the attention of the global pharmaceutical industry but has also given countless patients new hope. Why are … Read more
One patient had all tumor target lesions disappear, achieving complete remission,80% of patients experienced significant tumor reduction, and the novel GCC19CAR-T brings new hope to patients with advanced colorectal cancer! Globally, colorectal cancer (CRC) has become the third most common malignant tumor and the second leading cause of cancer-related deaths. Currently, metastatic colorectal cancer primarily … Read more
Introduction The DS8201-A-U105 study reveals the latest advancements in ADC combined immunotherapy. What insights can we draw from it? The annual European Society for Medical Oncology Breast Cancer (ESMO BC) conference was officially held from May 3-5, 2022, reporting a series of significant advancements in the field of breast cancer. ADCs have become star drugs … Read more
Not all long-established ADC Biotechs can achieve a successful exit like Seagen (Seattle Genetics). Today, Mersana Therapeutics, a 23-year-old veteran biotech, has reached its most desperate moment. With a cumulative deficit of $900 million and only $134.6 million left in cash, its two core pipeline products are still in Phase I clinical trials. To sustain … Read more